Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Return on Equity: 2021-2023

Historic Return on Equity for Cullinan Therapeutics (CGEM) over the last 2 years, with Sep 2023 value amounting to -0.32%.

  • Cullinan Therapeutics' Return on Equity fell 49.00% to -0.32% in Q3 2023 from the same period last year, while for Sep 2023 it was -0.32%, marking a year-over-year decrease of 49.00%. This contributed to the annual value of 0.23% for FY2022, which is 44.00% up from last year.
  • Latest data reveals that Cullinan Therapeutics reported Return on Equity of -0.32% as of Q3 2023, which was down 11.96% from -0.29% recorded in Q2 2023.
  • In the past 5 years, Cullinan Therapeutics' Return on Equity registered a high of 0.21% during Q2 2022, and its lowest value of -0.32% during Q3 2023.
  • Over the past 3 years, Cullinan Therapeutics' median Return on Equity value was -0.01% (recorded in 2021), while the average stood at -0.03%.
  • As far as peak fluctuations go, Cullinan Therapeutics' Return on Equity spiked by 35bps in 2022, and later plummeted by 50bps in 2023.
  • Over the past 3 years, Cullinan Therapeutics' Return on Equity (Quarterly) stood at -0.15% in 2021, then surged by 35bps to 0.19% in 2022, then plummeted by 49bps to -0.32% in 2023.
  • Its Return on Equity was -0.32% in Q3 2023, compared to -0.29% in Q2 2023 and 0.13% in Q1 2023.